Drugs / CALRLong36
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03566446 | Jun 2018 → Feb 2020 | essential thrombocythemia, myelofibrosis, myeloproliferative neoplasm, unclassifiable | Inge Marie Svane | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CALRLong36 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03566446 ↗ |